Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
Antonio Ascione(Ospedale Antonio Cardarelli), N. Caporaso(Federico II University Hospital), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Gioacchino Angarano(University of Bari Aldo Moro), Edoardo G. Giannini(Ospedale Policlinico San Martino), Benedetta Canovari(Ospedali Riuniti Marche Nord), A. Benedetti(Marche Polytechnic University), Guglielmo Borgia(University of Naples Federico II), A. Albertí(University of Padua), Vincenza Calvaruso(University of Palermo), Luca Fontanella(Fatebenefratelli Hospital), Nicola Boffa(Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona), Vincenzo Messina(Ospedale Sant'Anna), Anna Linda Zignego(University of Florence), Antonio Gasbarrini(Università Cattolica del Sacro Cuore), Andrea Antinori(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Mario Melazzini(Istituti Clinici Scientifici Maugeri), Simona Montilla(Italian Medicines Agency), Marco Marzioni(Marche Polytechnic University), Vincenzo Sangiovanni(Ospedale Sant'Anna), Paolo Calabrese(Italian Medicines Agency), Giuseppe Abbati(Italian Medicines Agency), M. Barone(University of Bari Aldo Moro), Alessio Aghemo, Vanni Borghi(University of Modena and Reggio Emilia), M. Angélico, Erica Villa(University of Modena and Reggio Emilia), Massimo Andreoni(University of Rome Tor Vergata), Chiara Boarini(Italian Medicines Agency), Salvatore Petta(University of Palermo), Irene Cacciola(University of Messina), Davide Campagnolo, Raffaele Bruno(University of Pavia), Pietro Andreoné, Maria Paola Trotta(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Maurizia Rossana Brunetto(University of Pisa), Lucio Boglione(Ospedale Amedeo di Savoia), Cinzia Antonini(Italian Medicines Agency), Ivo Avancini(Italian Medicines Agency), Savino Bruno(Humanitas University), Debora Angrisani(Italian Medicines Agency), Pier Luigi Blanc(Italian Medicines Agency), Antonio Craxı̀(University of Palermo), M. De Luca(Observatoire de Paris), Giuseppina Brancaccio, A. Orlandini(University of Parma), Veronica Bernabucci(University of Modena and Reggio Emilia), Antonio Izzi(University of Palermo), Paolo Angeli(University of Padua)
Cited by 8
Related Papers
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
|Journal of Hepatology|2018|2.8k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k